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IMPORTANCE Common noninvasive to minimally invasive cosmetic dermatologic procedures
are widely believed to be safe given the low incidence of reported adverse events, but reliable
incidence data regarding adverse event rates are unavailable to date.
OBJECTIVE To assess the incidence of adverse events associated with noninvasive to
minimally invasive cosmetic dermatologic procedures, including those involving laser and
energy devices, as well as injectable neurotoxins and fillers.
DESIGN, SETTING, AND PARTICIPANTS A multicenter prospective cohort study (March 28,
2011, to December 30, 2011) of procedures performed using laser and energy devices, as well
as injectable neurotoxins and soft-tissue augmentation materials, among 8 geographically
dispersed US private and institutional dermatology outpatient clinical practices focused on
cosmetic dermatology, with a total of 23 dermatologists. Participants represented a
consecutive sample of 20 399 cosmetic procedures. Data acquisition was for 3 months (13
weeks) per center, with staggered start dates to account for seasonal variation.
EXPOSURES Web-based data collection daily at each center to record relevant procedures, by
category type and subtype. Adverse events were detected by (1) initial observation by
participating physicians or staff; (2) active ascertainment from patients, who were
encouraged to self-report after their procedure; and (3) follow-up postprocedural phone calls
to patients by staff, if appropriate. When adverse events were not observed by physicians but
were suspected, follow-up visits were scheduled within 24 hours to characterize these
events. Detailed information regarding each adverse event was entered into an online form.
MAIN OUTCOMES AND MEASURES The main outcome was the total incidence of
procedure-related adverse events (total adverse events divided by total procedures
performed), as verified by clinical examination.
RESULTS Forty-eight adverse events were reported, for a rate of 0.24% (95% CI,
0.18%-0.31%). Overall, 36 procedures resulted in at least 1 adverse event, for a rate of 0.18%
(95% CI, 0.13%-0.25%). No serious adverse events were reported. Adverse events were
infrequently associated with known risk factors.
CONCLUSIONS AND RELEVANCE Noninvasive to minimally invasive cosmetic dermatologic
procedures, including energy, neurotoxin, and filler procedures, are safe when performed by
experienced board-certified dermatologists. Adverse events occur in less than 1% of patients,
and most of these are minor and transient.
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C osmetic dermatology is a well-developed field that in-cludes various procedures that are, individually, safeand effective. Combining these procedures may pro-
duce results comparable to those associated with more inva-
sive cosmetic procedures.
Few studies report serious or frequent adverse events
from cosmetic dermatologic interventions. Published data
suggest that cosmetic dermatologic procedures are associ-
ated with a low rate of adverse events. However, adverse
event intraprocedural or postprocedural incidence is in gen-
eral not well described in the literature. Obstacles to collec-
tion of detailed adverse event data include a lack of a
national or regional registry of procedures, the absence of
public or private funding to support data gathering, and
logistic and regulatory hurdles that complicate multicenter
studies. Postmarketing safety data that are available tend to
be fragmented, relevant to one or a few procedures, and
usually derived from a single practice.
The objective of this study was to use a multicenter pro-
spective cohort data collection strategy to characterize the in-
cidence of adverse events associated with a subset of com-
mon cosmetic dermatologic procedures. Specifically, these
included noninvasive to minimally invasive procedures in-




Study procedures were performed under the authorization
of the Northwestern University Institutional Review Board,
which authorized data collection and managed transmittal
of deidentified data across institutions to enable analysis.
Consent was waived because no personal identifiers were
collected.
This was a multicenter prospective cohort study of con-
secutive procedures performed using laser and energy de-
vices, as well as injectable neurotoxins and soft-tissue aug-
mentation materials, at geographically dispersed US private and
institutional cosmetic dermatology outpatient centers. Most
procedures were performed solely by board-certified derma-
tologists, but a few laser and energy device treatments were
performed by mid-level clinicians, including physician assis-
tants and nurse practitioners, under direct supervision of
board-certified dermatologists who were present in the of-
fice at the time. In these cases where mid-level clinicians as-
sisted with treatments, device settings and treatment proto-
cols were predetermined in consultation with supervising
board-certified dermatologists; in addition, all mid-level cli-
nicians had previously received formal hands-on training, as
well as classroom instruction, on the use of the specific de-
vices they operated.
Data acquisition occurred for 3 months (13 weeks) per cen-
ter, with the start dates staggered over 6 months to minimize
bias associated with seasonal variation in patient presenta-
tion. Data collection was accrued directly on the DermBase
web-based interface described previously.1
Participating Centers
Centers were selected to provide geographic diversity and to pro-
vide technique diversity, with efforts made to avoid recruiting
multiple physicians trained at the same institutions. All treat-
ing physicians were board-certified dermatologists in practice
for 5 years or more. Key nonphysician study personnel (R.K. and
N.P.) identified by the lead physician at each center were trained
on data acquisition and reporting by personnel at the coordi-
nating center. Data pertaining to the numbers and types of cos-
metic procedures performed, as well as detailed information
about adverse events, were uploaded each working day to the
DermBase site from each participating center.
Data Collection Forms
Two principal data evaluation forms were used. These were
(1) the Weekly Questionnaire (closed weekly but with daily data
entry in day-specific columns), which recorded the numbers
of laser and energy device procedures, as well as injectable neu-
rotoxin and filler procedures, by category type and subtype,
and (2) an Adverse Event Reporting Form that included de-
tailed clinical information, which was completed when any un-
expected adverse events were reported.
Covariates collected for practices surveyed were practice
type, practice setting (ie, urban, suburban, or rural), practice
location (ie, geographic region), and the median physician years
of experience. For all cases, covariates collected included the
anatomic area receiving treatment, the type of treatment, and
the specific device or drug used.
Additional covariates collected for patients with adverse
events included sex, age, Fitzpatrick skin type, medical his-
tory, risk factors, and specific types of adverse events. Infec-
tion was assessed by clinical impression and by culture posi-
tivity, and during data analysis either was deemed sufficient
to label the case as infected. Notably, this study was not de-
signed to assess delayed adverse events associated with cos-
metic procedures. Similarly, this study was not designed to de-
tect the incidence of transient, self-limited, and spontaneously
resolving erythema, edema, discomfort, or mild ecchymo-
ses, events that are associated with normal postprocedural
healing after minimally invasive cosmetic procedures.
Data Reporting and Collection Procedures and Controls
All sites were prospectively asked to track all complications
actively for the duration of the study. Any adverse event ini-
tially observed or detected by participating physicians or
their staff was reported. At the time of procedure perfor-
mance, patients were also asked to be vigilant about poten-
tial adverse events for at least 1 month and to promptly
report any unexpected results by phone to the office of the
treating physician. To further ensure appropriate ascertain-
ment of adverse events, treating physicians or their repre-
sentatives were asked to contact patients by phone within 1
week of the procedure to query patients regarding any
signs, symptoms, and events requiring medical care.
Patients reporting adverse events were offered a clinic
appointment within 24 hours. Follow-up visits were per-
formed when patients reported adverse events or when
physicians suspected adverse events. At such visits, an
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appropriate history was elicited, and physical examinations
were conducted to ascertain the signs and symptoms, as
well as any patient reports of previous adverse events that
had resolved before presentation. Follow-up visits were
staffed by study physicians, with nonphysician extenders
also seeing the patients in some cases.
Outcome Measures
The main outcome measure was the total incidence of proce-
dure-related adverse events, as verified by clinical examina-
tion. Secondary outcomes included the rates of particular types
of adverse events and the rates at which different procedures
were associated with adverse events.
Statistical Analysis
All data were analyzed descriptively, with means, medians, and
ranges for continuous measures and percentages for categori-
cal variables. Overall adverse event rates were computed, and
the rates were also computed by procedure type. In addition,
it was determined what percentage of procedures resulted in
at least 1 adverse event.
Results
For a 9-month period (39 weeks), from March 28, 2011, to
December 30, 2011, each of 8 centers for cosmetic dermatol-
ogy (23 physicians) in the United States (Table 1) prospec-
tively collected data for 13 consecutive weeks. A total of
20 399 procedures were studied. Forty-eight adverse events
were reported, for an adverse event rate of 0.24% (95% CI,
0.18%-0.31%). Reported adverse events occurred following
36 procedures; therefore, 0.18% (95% CI, 0.13%-0.25%) of
procedures resulted in at least 1 adverse event. No serious
adverse events were reported. Adverse events were uncom-
monly associated with known risk factors. Adverse events
most commonly occurred after procedures on the cheeks,
followed by nasolabial and eyelid procedures. Demographic
and medical information of patients experiencing adverse
events is summarized in Table 2 and Table 3, respectively.
Overall adverse event incidence and rate by procedure type
are summarized in Table 4, and Table 5 lists the frequencies
of specific adverse events by procedure type.
The dropout rate for in-person follow-up visits for pa-
tients reporting adverse events by phone was 0.0%. All pa-
tients who reported adverse events came in for at least 1 post-
operative management visit.
Table 3. Medical Information of 36 Patients
Experiencing Adverse Events
Variable No. (%)
Disease or chronic illness
Hypertension 1 (2.8)
Herpes simplex 1 (2.8)
Other risk factor for adverse event
Tobacco use of any kind 2 (5.6)
Habitual suntanning 2 (5.6)
Use of topical retinoids 2 (5.6)
Anticoagulant use of any kind 1 (2.8)
Implanted appliance 1 (2.8)
Preexisting infection 1 (2.8)












Table 1. Characteristics of 23 Physicians at 8 Study Centers
Variable Value
Study center practice type
Private 7
Academic 1
No. of physicians per study center 2.9
Physician years of experience, median (IQR) 18 (9-24)
Physician age, median (IQR), y 51 (42-56)
Physician sex, No. (%)
Male 13 (56.5)
Female 10 (43.5)





No. of cosmetic procedures performed
during the entire study
Mean 2550
Median (IQR) 2809 (2202-3260)
Abbreviation: IQR, interquartile range.







Median (IQR) 52 (27-82)





Abbreviation: IQR, interquartile range.
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Discussion
This multicenter prospective study of a large cohort of con-
secutively performed cosmetic procedures demonstrates that
adverse events are uncommon after minimally invasive and
noninvasive laser, energy device, filler, and neurotoxin pro-
cedures. The adverse events per procedure, as well as the pro-
portion of procedures associated with at least 1 adverse event,
were less than 0.5%. Most adverse events were types that would
be expected to resolve with treatment over weeks or months.
Significantly, no serious adverse events were reported.
While all the constituent adverse event rates were low, the
rates for fillers were slightly higher than those for energy de-
vices and neurotoxins. However, this is to be expected be-
cause among noninvasive and minimally invasive proce-
dures fillers are slightly more invasive than lasers and
neurotoxins. The more viscous prepackaged injectable fillers
(Perlane [Valeant/Galderma], Juvederm Ultra Plus [Allergan],
and Radiesse [Merz Aesthetics]) were associated with margin-





















All lasers and energy devices 9769 11 0.11 13 0.13 Hyperpigmentation
All lasers 7991 7 0.09 9 0.11 Hyperpigmentation
Pulsed-dye laser 2226 1 0.04 1 0.04 Ulceration
Q-switched ruby, Nd:YAG, alexandrite 2174 3 0.14 5 0.23 Hyperpigmentation
Fractional non–carbon dioxide 1156 2 0.17 2 0.17 Persistent erythema
Long pulsed 463 0 0 0 0 None
1927 nm 452 0 0 0 0 None
Potassium-titanyl-phosphate 448 0 0 0 0 None
Fractional carbon dioxide 394 0 0 0 0 None
Diode 299 0 0 0 0 None
Er:YAG 255 0 0 0 0 None
Mid-infrared 64 1 1.56 1 1.56 Persistent purpura
Nonfractional carbon dioxide pulsed 41 0 0 0 0 None
Yttrium-scandium-gallium-garnet 19 0 0 0 0 None
Intense pulsed light 500-1200 nm 596 2 0.34 2 0.34 Hyperpigmentation, burn
All radiofrequency 461 1 0.22 1 0.22 Burn
Monopolar 352 0 0 0 0 None
Other noninvasive radiofrequency 90 0 0 0 0 None
Invasive radiofrequency 18 1 5.56 1 5.56 None
Bipolar 1 0 0 0 0 None
Ultrasound 467 0 0 0 0 None
Cryolipolysis 254 1 0.39 1 0.39 Persistent dysesthesia
All neurotoxins and fillers 10 630 25 0.24 35 0.33 Lump, nodule, beading
All fillers 4430 23 0.52 33 0.74 Lump, nodule, beading
Restylane (Valeant/Galderma) 1697 5 0.29 8 0.47 Lump, nodule, beading
Juvederm Ultra (Allergan) 1549 8 0.52 8 0.52 Lump, nodule, beading
Sculptra (Valeant/Galderma) 357 2 0.56 2 0.56 Lump, nodule, beading
Radiesse (Merz Aesthetics) 379 3 0.79 9 2.37 Occlusion, necrosis
Juvederm Ultra Plus (Allergan) 343 3 0.87 3 0.87 Lump, nodule, beading;
granuloma; filler migration
Perlane (Valeant/Galderma) 81 1 1.23 1 1.23 Sign or symptom of infection
Fat 15 0 0 0 0 None
Silicone 6 1 16.7 2 33.3 Lump, nodule, beading; granuloma
ArteFill (Suneva Medical) 3 0 0 0 0 None
All neurotoxins 6200 2 0.03 2 0.03 Hematoma, ptosis
Onabotulinum toxin A 4624 2 0.04 2 0.04 Hematoma, ptosis
Abobotulinum toxin A 1576 0 0 0 0 None
Total 20 399 36 0.18 48 0.24 Lump, nodule, beading
a Some procedures resulted in more than 1 type of adverse event.
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ally but not significantly higher adverse event rates, in the range
of 1% to 2%. Overall, the aggregate adverse event rate for in-
jectable fillers was only 0.52% and was composed mostly of
cases of lumps (which would be amenable to immediate treat-
ment) and purpura (which would be expected to resolve spon-
taneously). The adverse event rate found for injectable fillers
is markedly and remarkably lower than associated rates for per-
manent implants requiring a surgical incision.
Most energy device procedures studied were nonablative
laser procedures. Hyperpigmentation was the most common
adverse event for energy-related procedures but was still un-
common as a function of procedures performed. This inci-
dence of hyperpigmentation may be slightly higher than pre-
viously thought because of increases in recent years in the
proportion of laser patients with skin of color, who are slightly
more susceptible to this outcome even under optimal condi-
tions. Again, most cases of hyperpigmentation can be ex-
pected to resolve spontaneously.
This study has limitations. While the overall number of
cases studied is high, cases are not distributed evenly across
procedure categories and subcategories. As a result, sub-
group data are less useful for estimating the adverse event rates
of specific procedures, particularly those that are less fre-
quently performed. For instance, no adverse events were re-
ported after ablative carbon dioxide resurfacing, and only 1 ad-
verse event was reported after pulsed-dye laser treatment.
However, because 2226 pulsed-dye treatments were deliv-
ered and only 41 laser resurfacing cases were performed, it is
unreasonable to suggest that pulsed-dye laser may be more
prone to induce adverse events than carbon dioxide laser. An-
other limitation is that, even when comparable numbers of re-
lated procedures are performed, a single case can potentially
skew the relative adverse event rates given the low absolute
adverse event rates. Within the subcategory of viscous pre-
packaged fillers, while the 3 more viscous agents listed above
are similar in the proportion of procedures associated with ad-
verse events, the number of adverse events per procedure is
higher for Radiesse because of a single case that was associ-
ated with 7 reported adverse events. Even including this case,
the proportion of cases associated with at least 1 adverse event
is actually somewhat lower for Radiesse than for the other 2
products. Finally, ascertainment of adverse events that oc-
curred more than 1 month after a procedure was variable in fre-
quency across centers because no protocol-based recommen-
dation exists for this. However, because most adverse events
associated with cosmetic dermatologic procedures likely mani-
fest within 1 month, this was not considered a major cause of
underreporting.
As with all studies of a range of procedures performed by
several different physicians, this study is subject to bias asso-
ciated with differences in technique and overall skill level. For
instance, if viscous fillers are diluted by some physicians with
lidocaine, the resulting slurry may be less prone to induce
bumps or vasoocclusion.
Table 5. Frequencies of Specific Adverse Events by Procedure Typea
Adverse Event
No. (%) of 48 Overall
Adverse Events Procedure Type
Lump, nodule, beading 11 (22.9) 5 Juvederm Ultra, 1 Juvederm Ultra Plus, 2 Restylane,
2 Sculptra, 1 silicone
Hyperpigmentation 4 (8.3) 3 Nd:YAG, 1 intense pulsed light
Persistent purpura 4 (8.3) 1 Mid-infrared, 2 Juvederm Ultra, 1 Restylane
Ulceration 4 (8.3) 1 Pulsed-dye laser, 1 Nd:YAG, 1 Radiesse, 1 Restylane
Burn 3 (6.3) 1 Nd:YAG, 1 intense pulsed light, 1 invasive
radiofrequency
Granuloma 3 (6.3) 1 Juvederm Ultra Plus, 1 Radiesse, 1 silicone
Occlusion 2 (4.2) 1 Radiesse, 1 Restylane
Sign or symptom of infection 2 (4.2) 1 Radiesse, 1 Perlane
Necrosis 2 (4.2) 2 Radiesse
Persistent dysesthesia 1 (2.1) 1 Cryolipolysis
Persistent erythema 1 (2.1) 1 Fractional non–carbon dioxide
Abscess 1 (2.1) 1 Restylane
Altered smile 1 (2.1) 1 Radiesse
Cellulitis 1 (2.1) 1 Radiesse
Filler migration 1 (2.1) 1 Juvederm Ultra Plus
Hematoma 1 (2.1) 1 Botulinum toxin
Tyndall effect 1 (2.1) 1 Juvederm Ultra
Ptosis 1 (2.1) 1 Ptosis
Reticulate erythema 1 (2.1) 1 Restylane
Scarring 1 (2.1) 1 Radiesse
Texture irregularity 1 (2.1) 1 Restylane
Excessive bruising 1 (2.1) 1 Fractional non–carbon dioxide
Persistent edema 0 None
Serious adverse event 0 None
a Thirteen adverse events were
associated with the following lasers
and energy devices: 1 pulsed-dye
laser, 5 Nd:YAG, 2 fractional
non–carbon dioxide, 1 mid-infrared,
2 intense pulsed light, 1 invasive
radiofrequency, and 1 cryolipolysis.
Thirty-five adverse events were
associated with the following
neurotoxins and fillers: 2 botulinum
toxin, 8 Juvederm Ultra (Allergan),
3 Juvederm Ultra Plus (Allergan),
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Significantly, this study only studied the safety of cos-
metic procedures performed by board-certified dermatolo-
gists. Other providers, possibly with less training in specific
procedures and more limited understanding of facial anatomy,
skin physiology, and wound healing, may perform these pro-
cedures with variable safety.
Caveats aside, a notable finding of this study was that simi-
lar but not identical proprietary substances had similar ad-
verse event rates. Not only were viscous prepackaged fillers
similar with regard to adverse event rates but so also were the
less viscous fillers and the neurotoxins.
Prior investigations of adverse events associated with cos-
metic dermatology procedures have been less extensive. Safety
studies that provide incidence data regarding adverse events
tend to be limited to those performed for initial Food and Drug
Administration drug or device approval. In some cases, fol-
low-on studies have been performed that pool the results of
pivotal trials or reenroll willing participants for a longer dura-
tion to improve generalizability or assess long-term safety.1-3
Few adverse event incidence data are available to describe cos-
metic procedure safety in routine clinical practice as treat-
ment strategies and approaches evolve beyond those studied
in controlled populations for regulatory approval. Most re-
views and discussions of adverse events have focused on the
manifestations and management of adverse events and have
not attempted to estimate their incidences.4-7 Adverse event
studies that include a denominator signifying the total num-
ber of cases performed tend to be multiyear retrospective co-
hort studies of a single, busy physician, with the attendant re-
call and reporting bias. For particular drugs or devices,
consensus recommendations are often developed by review-
ing the results of a few major centers several years after regu-
latory approval, but these tend to focus on evolving refine-
ments in technique designed to maximize safety and
effectiveness, rather than estimation of adverse event rates per
se.8 Adverse event data for cutaneous lasers and energy de-
vices are fragmented because of the many dozens if not hun-
dreds of different devices in this category, and each tends to
be studied separately.9 The present study is novel in that it en-
tailed (1) active ascertainment of adverse events to minimize
underreporting, (2) a prospective design to minimize recall bias,
and (3) multicenter data collection to reduce bias associated
with differences in physician technique.
Conclusions
To our knowledge, this study is the first large multicenter pro-
spective cohort study that estimates adverse event rates as-
sociated with major categories of cosmetic dermatologic pro-
cedures, including laser and energy device procedures, as well
as injectable fillers and neurotoxins. In the hands of well-
trained dermatologists, these procedures are safe, with aggre-
gate adverse event rates of well under 1%. Moreover, most ad-
verse events are minor and rapidly remitting, and serious
adverse events were not seen. Patients seeking such proce-
dures can be reassured that, at least in the hands of trained
board-certified dermatologists, they pose minimal risk.
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The Greatest Syphilographer of All Time
Ismaël Maatouk, MD; Roy Moutran, MD
Jonathan Hutchinson is recognized as the foremost British syphilologist
of the 19th century. His interest in syphilis began early in his career, in 1849,
when he described 2 cases of keratitis associated with congenital syphilis
(CS).1 He realized later that very little had been written about CS.1
He had noted a peculiar development of the permanent teeth, par-
ticularly the upper incisors, in patients with CS.1 Hutchinson’s observa-
tion had been greeted with expressions of incredulity, so he decided to
publish details of 13 cases followed later by details of 70 cases.1 At the
same time, he published the results of his studies of the association be-
tween CS and interstitial keratitis. The old term strumous corneitis, which
implied a connection with tuberculosis, was abandoned as meaning-
less in this context. Hutchinson's conclusion was a new idea, and for many
years it was not accepted.1
In 1861, Hutchinson wrote an article on deafness accompanying CS,
but he characterized it more fully in his Clinical Memoir (1863): it affects
older children or adults and is eventually bilateral. Thus, “Hutchinson's triad”
was complete and became a password in the profession, and at 35 years
of age, Hutchinson became the specialist in the “'great imitator” as he
named the disease. In 1876, he stated that syphilis was “a disease which
could affect the skin and internal organs.”1 In 1879 he described how syphi-
lis could mimic a multitude of skin, eye, and neurological disorders.1 In 1887,
18 years before Treponema pallidum was discovered, Hutchinson stated
that syphilis depends on a “living and specific microbe.”1
Hutchinson advocated mercury for the treatment of early syphilis;
unlike many of his contemporaries, he believed that treatment should
be started immediately after the diagnosis was made.1 He often com-
bined iodides with mercury in cases of late syphilis. Hutchinson was
doubtful of the value of organic arsenicals introduced by Ehrlich in
1906.2
Hutchinson’s study of individual case histories is shown in the first
edition of his book Syphilis1 dedicated to Fournier. (The second edition,
largely rewritten, appeared in 1909.2)
It was probably his interest in syphilis that led him into the field of
dermatology, ophthalmology and surgery.2
Hutchinson’s interest in museums arose from his ideas of objective
teaching. At the British Medical Association meeting in 1868, he sug-
gested that an annual exhibition of models be arranged to mark the year's
progress. From this suggestion has arisen the system of scientific ex-
hibit that is now a part of medical conventions.
By his death in 1913, at the age of 85 he had been appointed as the
chair of every important medical society in England. He had reached the
top in ophthalmology, dermatology, and surgery, and history will prob-
ably pronounce him the greatest syphilographer of all time.
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